Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus paclitaxel liposome and nedaplatin as neoadjuvant therapy for esophageal squamous cell carcinoma
ChiCTR2000028840Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Feb 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib, paclitaxel and nedaplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Objective response rate and Pathological complete response rate. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
anlotinibpaclitaxelnedaplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000028840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028840.